» Articles » PMID: 17368038

ABC Transporter Expression in Hematopoietic Stem Cells and the Role in AML Drug Resistance

Overview
Specialty Hematology
Date 2007 Mar 21
PMID 17368038
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

ATP-binding cassette (ABC) transporters are known to play an important role in human physiology, toxicology, pharmacology, and numerous disorders including acute myeloid leukemia (AML). In AML only a few cells have properties allowing for ongoing proliferation and for expansion of this malignant disorder. These very primitive cells, referred to as leukemic stem cells, reside mostly in a quiescent cell cycle state. These cells have the capacity of self-renewal and are likely characterized by a high expression of a number of ABC transporters. In addition, over-expression of certain ABC transporters in leukemic cells has been associated with poor treatment outcome in AML patients. Therefore, to be able to improve diagnostics and therapies for AML patients, it may be important to better characterize this quiescent stem cell population. Particularly knowledge of the biology of highly expressed ABC transporters in these primitive leukemic cells might provide new insights to improve therapeutic options. This review provides an overview about ABC transporters and AML in general and particularly of the ABC transporters involved in multidrug resistance and cholesterol metabolism in primitive normal and leukemic cells.

Citing Articles

Recent trends in research on the role of cholesterol in leukemia: a bibliometric and visualization study.

Lv H, Lu K, Wang X, Zhang Y, Zhuang M, Li J Front Immunol. 2025; 16:1511827.

PMID: 39917295 PMC: 11799240. DOI: 10.3389/fimmu.2025.1511827.


Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia.

Verhagen N, Koenderink J, Blijlevens N, Janssen J, Russel F Pharmaceutics. 2023; 15(11).

PMID: 38004514 PMC: 10675650. DOI: 10.3390/pharmaceutics15112535.


ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia.

Ebner J, Schmoellerl J, Piontek M, Manhart G, Troester S, Carter B Nat Commun. 2023; 14(1):5709.

PMID: 37726279 PMC: 10509209. DOI: 10.1038/s41467-023-41229-2.


Targeting CD38 in Neoplasms and Non-Cancer Diseases.

Szlasa W, Czarny J, Sauer N, Rakoczy K, Szymanska N, Stecko J Cancers (Basel). 2022; 14(17).

PMID: 36077708 PMC: 9454480. DOI: 10.3390/cancers14174169.


Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.

Niu J, Peng D, Liu L Front Oncol. 2022; 12:896426.

PMID: 35865470 PMC: 9294245. DOI: 10.3389/fonc.2022.896426.